0000000000580495

AUTHOR

M. Lopez

showing 8 related works from this author

FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM)

2005

Purpose: To verify the experience of the GOIM in the treatment of advanced colorectal cancer patients with the FOLFIRI combination therapy. Patients and methods: Patients entered in three consecutive trials of the GOIM (protocols no. 9706, 9901, and 2301) were reported in this analysis. A total of 287 chemotherapy-naive patients were treated with FOLFIRI regimen: Irinotecan 180mg/m 2 on day 1 with LV5FU2 regimen (LV at 100mg/m 2 administered as a 2-hour infusion before FU at 400mg/m 2 as an intravenous bolus injection, and FU at 600mg/m 2 as a 22-hour infusion immediately after 5FU bolus injection on day 1 and 2); the treatment was repeated every 2 weeks. Results: 287 patients entered in th…

AdultMalemedicine.medical_specialtyOrganoplatinum CompoundsCombination therapyColorectal cancerLeucovorinGastroenterologyFolinic acidInternal medicineAntineoplastic Combined Chemotherapy ProtocolsFOLFIRI RegimenHumansMedicineAgedSulfonamidesbusiness.industryCarcinomaLiver NeoplasmsHematologyMiddle Agedmedicine.diseaseSurgeryIrinotecanRegimenTreatment OutcomeOncologyCelecoxibFluorouracilFOLFIRIPyrazolesCamptothecinFemaleFluorouracilColorectal Neoplasmsbusinessmedicine.drugAnnals of Oncology
researchProduct

A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by E…

2011

Background: The Gruppo Oncologico Italia Meridionale 9902 trial compared four cycles of high-dose epirubicin plus cyclophosphamide (EC) with four cycles of docetaxel (Taxotere, D) followed by four cycles of EC as adjuvant treatment of node-positive breast cancer. Patients and methods: Patients were randomly assigned to EC (E 120 mg/m 2 , C 600 mg/m 2 , arm A) for four cycles or four cycles of D (100 mg/m 2 ) followed by four cycles of EC (arm B), both regimens every 21 days. Hormone receptor-positive patients were given hormonal therapy for 5 years. Primary end point was 5-year disease-free survival (DFS). Secondary objectives were overall survival (OS) and safety. Results: There were 750 p…

AdultOncologymedicine.medical_specialtyCyclophosphamideBreast NeoplasmsDocetaxelDisease-Free SurvivalBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesProspective cohort studyCyclophosphamideSurvival analysisEpirubicinGynecologyDose-Response Relationship Drugbusiness.industryCarcinomaHazard ratioOriginal ArticlesHematologyMiddle Agedmedicine.diseaseSurvival AnalysisItalyOncologyDocetaxelLymphatic MetastasisHormonal therapyFemaleTaxoidsLymph NodesbusinessAlgorithmsmedicine.drugEpirubicinAnnals of Oncology
researchProduct

Sensitivity of the Cherenkov Telescope Array for probing cosmology and fundamental physics with gamma-ray propagation

2021

Full list of authors: Abdalla, H.; Abe, H.; Acero, F.; Acharyya, A.; Adam, R.; Agudo, I; Aguirre-Santaella, A.; Alfaro, R.; Alfaro, J.; Alispach, C.; Aloisio, R.; Batista, R. Alves; Amati, L.; Amato, E.; Ambrosi, G.; Anguner, E. O.; Araudo, A.; Armstrong, T.; Arqueros, F.; Arrabito, L.; Asano, K.; Ascasibar, Y.; Ashley, M.; Backes, M.; Balazs, C.; Balbo, M.; Balmaverde, B.; Baquero Larriva, A.; Martins, V. Barbosa; Barkov, M.; Baroncelli, L.; de Almeida, U. Barres; Barrio, J. A.; Batista, P-, I; Becerra Gonzalez, J.; Becherini, Y.; Beck, G.; Tjus, J. Becker; Belmont, R.; Benbow, W.; Bernardini, E.; Berti, A.; Berton, M.; Bertucci, B.; Beshley, V; Bi, B.; Biasuzzi, B.; Biland, A.; Bissaldi, …

Gamma ray AstronomyCherenkov Telescope ArrayaxionsMATÉRIA ESCURAredshift: dependenceAstronomyGamma ray experimentsgamma ray experimentsAstrophysics01 natural sciencesCosmologyObservatorycosmological model: parameter spacegamma ray experimentHigh Energy Astrophysical Phenomena (astro-ph.HE)astro-ph.HEPhysicsCherenkov telescopes ; IACT technique ; Gamma rays ; Cosmic raysnew physics4. EducationSettore FIS/01 - Fisica SperimentaleAstrophysics::Instrumentation and Methods for AstrophysicsGamma-ray astronomyviolation: Lorentz3. Good healthobservatoryExtragalactic background lightastro-ph.COaxion-like particlesFísica nuclearAstrophysics - High Energy Astrophysical PhenomenaAstrophysics - Cosmology and Nongalactic Astrophysicsgamma ray: propagationCosmology and Nongalactic Astrophysics (astro-ph.CO)Active galactic nucleusAxionsAstrophysics::High Energy Astrophysical PhenomenaDark matterFOS: Physical sciencesAstrophysics::Cosmology and Extragalactic Astrophysicsinvariance: Lorentzjet: relativisticdark matter: halo0103 physical sciencesactive galactic nuclei; gamma ray experiments; axions; extragalactic magnetic fieldsAGNBlazarbackground010308 nuclear & particles physicsFísicaAstronomy and AstrophysicssensitivityCherenkov Telescope Arrayaxionextragalactic magnetic fieldsactive galactic nuclei[PHYS.ASTR]Physics [physics]/Astrophysics [astro-ph]absorptionstatisticalBlazarsTelescopes
researchProduct

5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: A multicenter randomised phase II study of the Souther…

2000

The combination regimen CPT-11 plus bolus and infusion 5-fluorouracil (5-FU) with high-dose leucovorin (hybrid regimen LV5FU2) has been tested for activity and toxicity against advanced colorectal carcinoma in a randomised, multicenter phase II trial.A total of 102 chemotherapy-naïve patients were randomised in a 1:2 fashion to receive: leucovorin 100 mg/m2 administered as a two-hour infusion before 5-FU 400 mg/m2 as an intravenous bolus, and FU 600 mg/m2 as a 22-hour infusion immediately after 5-FU bolus injection repeated on days 1 and 2 (LV5FU2 regimen, arm A, 34 patients) or CPT-11 at 180 mg/m2 (150 mg/m2 for patients of ageor = 70 and75 years) only on day 1 immediately before LV5FU2 th…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentLeucovorinPhases of clinical researchIrinotecanGastroenterologyDisease-Free SurvivalFolinic acidBolus (medicine)Internal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansInfusions IntravenousAgedChemotherapybusiness.industryHematologyMiddle AgedChemotherapy regimenSurgeryIrinotecanRegimenTreatment OutcomeOncologyFluorouracilInjections IntravenousCamptothecinFemaleFluorouracilColorectal Neoplasmsbusinessmedicine.drugAnnals of Oncology
researchProduct

VizieR Online Data Catalog: 46 open clusters GaiaDR2 HR diagrams (Gaia Collaboration, 2018)

2018

We have determined the membership of 46 open clusters. For the nine clusters within 250pc we determined optimised parallaxes based on the combined information extracted from the measured parallax and proper motion values. These clusters are : in Tables A1a & A3: alphaPer, Blanco1, ComaBer, Hyades, IC2391, IC2602, NGC2451A, Pleiades, Praesepe. The remaining 37 clusters are in Table A1b & A4: Coll140, IC4651, IC4665, IC4725, IC4756, NGC0188, NGC0752, NGC0869, NGC0884, NGC1039, NGC1901, NGC2158, NGC2168, NGC2232, NGC2323, NGC2360, NGC2422, NGC2423, NGC2437, NGC2447, NGC2516, NGC2547, NGC2548, NGC2682, NGC3228, NGC3532, NGC6025, NGC6281, NGC6405, NGC6475, NGC6633, NGC6774, NGC6793, NGC7092, Sto…

[SDU.ASTR.IM] Sciences of the Universe [physics]/Astrophysics [astro-ph]/Instrumentation and Methods for Astrophysic [astro-ph.IM]Parallaxes: trigonometricClusters: openProper motions
researchProduct

VizieR Online Data Catalog: Gaia DR2 sources in GC and dSph (Gaia Collaboration+, 2018)

2018

The files contains lists of possible members of each of the objects (75 globular clusters, 9 dwarf spheroidal galaxies, the Bootes I UFD, the LMC and SMC). The stars in these lists have been selected and used to determine the astrometric parameters of the corresponding objects following either the procedures described in Sec. 2.1 (for the clusters and dwarfs) or in Sec. 2.2 (for the LMC and SMC). The first column is the "source_id" as given by Gaia, the ra and declination of the star in degrees, and its G-band magnitude (known as "photgmean_mag" in the Gaia archive). (2 data files).

Galaxies: nearbyPositional data[SDU.ASTR.IM] Sciences of the Universe [physics]/Astrophysics [astro-ph]/Instrumentation and Methods for Astrophysic [astro-ph.IM]SurveysClusters: globular
researchProduct

SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study

2021

Abstract Background Preoperative SARS-CoV-2 vaccination could support safer elective surgery. Vaccine numbers are limited so this study aimed to inform their prioritization by modelling. Methods The primary outcome was the number needed to vaccinate (NNV) to prevent one COVID-19-related death in 1 year. NNVs were based on postoperative SARS-CoV-2 rates and mortality in an international cohort study (surgical patients), and community SARS-CoV-2 incidence and case fatality data (general population). NNV estimates were stratified by age (18–49, 50–69, 70 or more years) and type of surgery. Best- and worst-case scenarios were used to describe uncertainty. Results NNVs were more favourable in su…

MaleCOVID-19 Vaccinesafe surgery; vaccination modelling; COVID-19Vascular damage Radboud Institute for Health Sciences [Radboudumc 16]MULTICENTERComorbidity030230 surgery0302 clinical medicinephase 3 clinical trial (topic)Case fatality rateProspective StudiesSARS-CoV-2 Vaccination Safe surgeryCOVID-19/epidemiologySARS-CoV-2 ; vaccination ; safe surgeryeducation.field_of_studycase fatality rateVaccinationVaccinationAdolescent; Adult; Aged; COVID-19; COVID-19 Vaccines; Comorbidity; Elective Surgical Procedures; Female; Humans; Male; Middle Aged; Postoperative Complications; Preoperative Period; Prospective Studies; SARS-CoV-2; Vaccination; Young Adulthealth care policyElective Surgical Procedures030220 oncology & carcinogenesisvaccination modellingPreoperative PeriodCOVID-19; SARS-CoV-2; cancer; vaccination; outcome; mortality; infection; modellingCohort studyprospective studyHumanmedicine.medical_specialtyArticle03 medical and health sciencesSARS-CoV-2 vaccinationSDG 3 - Good Health and Well-beingCOVID-19 Vaccines/pharmacologyHumansVaccination/methodsElective surgeryeducationAgedScience & TechnologyElective Surgical Procedureadult; aged; Article; cancer grading; cancer surgery; case fatality rate; computer assisted tomography; elective surgery; female; follow up; health care policy; human; incidence; infection rate; infection risk; major clinical study; male; middle aged; mortality; outcome assessment; phase 3 clinical trial (topic); preoperative care; prospective study; sensitivity analysis; seroprevalence; Severe acute respiratory syndrome coronavirus 2; vaccination; young adult; COVID-19; COVID-19 Vaccines; Comorbidity; Elective Surgical Procedures; Postoperative Complications; Preoperative Period; SARS-CoV-2; Vaccination; surgery.Cura preoperatòriamajor clinical studymortalityinfectionProspective StudieincidenceSurgeryHuman medicinePostoperative Complication610 Medizin und GesundheitAcademicSubjects/MED00910Settore MED/18 - CHIRURGIA GENERALESettore MED/29 - CHIRURGIA MAXILLOFACCIALEcomputer assisted tomographyESTUDOS PROSPECTIVOSsurgerysafe surgeryPostoperative Complicationssensitivity analysisSevere acute respiratory syndrome coronavirus 2preoperative careVacunacióProspective cohort studyseroprevalenceIncidence (epidemiology)covidElective Surgical Procedures/methodsMiddle Agedcancer gradingCOVID vaccinationoutcome/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingSARS-CoV-2; vaccination; surgeryOriginal ArticleFemalecancer surgeryAcademicSubjects/MED00010Life Sciences & BiomedicineAdultCOVID-19 VaccinesAdolescentinternational prospective cohort studyPostoperative Complications/prevention & controlPopulationinfection rateSARS-CoV-2/immunologyNOmodellingYoung Adultmedicinefollow upcancerddc:610infection riskoutcome assessmentLS7_4business.industrySARS-CoV-2Number needed to vaccinatePreoperative careCOVID-193126 Surgery anesthesiology intensive care radiologySettore MED/18Reconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10]elective surgeryEmergency medicinebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe British Journal of Surgery
researchProduct

Petrology of some amphibole-bearing volcanics of the pre-Ellittico period (102-80 ka), Mt. Etna

2006

We present here petrological and geochemical data on volcanics cropping out in southern and northeastern walls of the Valle del Bove (Mt. Etna), belonging to the Rocche, Serra Giannicola Grande and Canalone della Montagnola Units. These units constitute the remnants of several volcanoes that were active in the time span 102-80 ka, i.e. before the growth of the Ellittico-Mongibello strato-volcano. Their products, range in composition from hawaiites to benmoreites. Amphibole (kaersutite) is present as phenocryst in all the studied rocks, and commonly shows breakdown coronas of rhönite ± clinopyroxene and plagioclase formed during magma ascent. Nevertheless, in mafic rocks, amphibole occurs as…

Settore GEO/07 - Petrologia E PetrografiaEtna Valle del Bove alkaline magmatism kaersutite rhönite
researchProduct